Clinical Trials Logo

Filter by:
NCT ID: NCT05314101 Recruiting - Colorectal Cancer Clinical Trials

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.

NCT ID: NCT05314010 Recruiting - Clinical trials for Neuromyelitis Optica Spectrum Disorder

A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Start date: August 18, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder.

NCT ID: NCT05313958 Recruiting - Pediatric AML Clinical Trials

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children

SCCLG-M5
Start date: December 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multicenter, single arm, prospective, intervention trial. Since cladribine can enhance the biological activity and self-protection of cytarabine, giving cladribine and cytarabine together may kill more cancer cells. 10 centers from South China Childhood Leukaemia Collaborative Group carry out the SCCLG-M5-2022 regimen including two courses of CLAG(cladribine, darubicin and cytarabine) in the induction period for the treatment of newly dignosed acute monocytic leukemia (M5). The targeted drugs sorafenib is used for FLT3 positive acute monocytic leukemia to inhibit the serine / threonine kinase activity of FLT3.

NCT ID: NCT05313854 Recruiting - Pancreatic Cancer Clinical Trials

Diagnosis and Survival Prediction of Pancreatic Cancer by Machine Learning of Image Data

Start date: January 1, 2021
Phase:
Study type: Observational

This prospective cohort study is designed to investigate the diagnostic ability and prediction accuracy of pancreatic cancer by radiomics data and clinical data.

NCT ID: NCT05313529 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Effects of Liraglutide, Empagliflozin and Linagliptin on the Cognitive Function in T2DM Patients With Mild Cognitive Impairment: a Multicenter, Randomized, Parallel Controlled Clinical Trial

LIGHT-MCI
Start date: October 8, 2022
Phase: N/A
Study type: Interventional

This is a prospective, randomized, open label, parallel, 76-week study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function, olfactory function, and odor-induced brain activation in T2DM patients with mild cognitive impairment (MCI).

NCT ID: NCT05313282 Recruiting - Clinical trials for C-staged Hepatocellular Carcinoma in BCLC Classification

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification

TRIPLET-III
Start date: June 15, 2022
Phase: Phase 3
Study type: Interventional

This study was designed to evaluate the effectiveness and safety of hepatic arterial infusion chemotherapy combined with Apatinib and Camrelizumab (treatment group) versus Apatinib and Camrelizumab (control group) for C-staged Hepatocellular Carcinoma in BCLC classification. The primary outcome measure is to evaluate the progression-free-survival (PFS) of treatment group and control group for C-staged Hepatocellular Carcinoma in BCLC classification. The secondary Outcome measures include the overall survival (OS), time to progress (TTP), time-to-response (TTR), duration of response (DOR), objective response rate (ORR) and disease control rate (DCR) of treatment group and control group for C-staged Hepatocellular Carcinoma in BCLC classification. Moreover, this study aims to assess the safety and tolerability of treatment group and control group for C-staged Hepatocellular Carcinoma in BCLC classification.

NCT ID: NCT05312840 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Cindilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

Start date: January 1, 2022
Phase: Phase 4
Study type: Interventional

To observe the efficacy and safety of conventional and low-dose platinum Gemcitabine combined with Cindilimab with delayed administration in first-line treatment of advanced squamous non-small cell lung cancer.

NCT ID: NCT05312476 Recruiting - Clinical trials for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Start date: February 10, 2022
Phase: Phase 2
Study type: Interventional

Aim of this study will evaluate the safety, tolerability and preliminary efficacy of chimeric antigen receptor T cells (CAR-T) targeting Igβ targets in patients with Igβ-positive refractory relapsed non-Hodgkin's lymphoma.

NCT ID: NCT05312463 Recruiting - Clinical trials for Gastroesophageal Reflux

Assessment on Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome

Start date: March 26, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Overlapping gastrointestinal symptoms of functional gastrointestinal diseases (FGIDs) is an internationally recognized problem in modern medical diagnosis and treatment. Such patients show more physical symptoms and worse quality of life, resulting in a huge economic burden. At present, FGIDs gastrointestinal symptoms overlap, lack of effective and systematic treatment, and the treatment goal is to improve symptoms.The study plans to carry out a multi center and large sample RCT clinical study of Tongjiang granule in the treatment of overlapping gastrointestinal symptoms of non erosive reflux disease(NERD)and epigastric pain syndrome(EPS, so as to provide high-level evidence-based evidence for the treatment of overlapping symptoms of FGIDs and form a diagnosis and treatment scheme that can be popularized.

NCT ID: NCT05312450 Recruiting - Diabetes Clinical Trials

TCM and Nutrition for Diabetes Care Cohort

TCM-Nut-DC
Start date: March 10, 2022
Phase:
Study type: Observational

This is a prospective cohort study that takes place in a clinic of Hangzhou, China. The aim of this study is to explore the molecular mechanism of special Chinese medicine formula combined with personalized nutrition to assist the treatment of diabetes from the aspect of multi-omics view. This study also aims to explore the relationship between gut microbiome and blood glucose in the process of personalized diet intervention.